Molecular Mechanisms of Preeclampsia

Cold Spring Harb Perspect Med. 2015 Aug 20;5(10):a023473. doi: 10.1101/cshperspect.a023473.

Abstract

Preeclampsia is a pregnancy-specific disease characterized by new onset hypertension and proteinuria after 20 wk of gestation. It is a leading cause of maternal and fetal morbidity and mortality worldwide. Exciting discoveries in the last decade have contributed to a better understanding of the molecular basis of this disease. Epidemiological, experimental, and therapeutic studies from several laboratories have provided compelling evidence that an antiangiogenic state owing to alterations in circulating angiogenic factors leads to preeclampsia. In this review, we highlight the role of key circulating antiangiogenic factors as pathogenic biomarkers and in the development of novel therapies for preeclampsia.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inducing Agents / metabolism
  • Angiogenesis Inducing Agents / therapeutic use
  • Biomarkers / metabolism*
  • Female
  • Humans
  • Placenta / metabolism
  • Placenta Diseases / diagnosis
  • Placenta Diseases / drug therapy
  • Placenta Diseases / etiology
  • Pre-Eclampsia / diagnosis
  • Pre-Eclampsia / drug therapy
  • Pre-Eclampsia / etiology*
  • Pregnancy
  • Prenatal Diagnosis / methods
  • Signal Transduction / physiology
  • Vascular Endothelial Growth Factor A / physiology
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism

Substances

  • Angiogenesis Inducing Agents
  • Biomarkers
  • Vascular Endothelial Growth Factor A
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1